# US 9,518,987 B2 · Prostate kallikrein allergen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,518,987 B2 - Document ID: US9518987B2 - Status: Granted - Kind: B2 - Application number: 14/930,737 - Filed: 2015-11-03 - Published: 2016-02-25 - Granted: 2016-12-13 - Earliest claimed: 2006-12-22 - Assignees: Phadia AB - Applicants: Phadia AB - Inventors: Lars Mattsson; Jonas Lidholm; Henrik Everberg - Web page: https://patentgrep.com/patent/US9518987B2 ## CPC - G01N 33/573: for enzymes or isoenzymes - A61K 39/35: Allergens - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C07K 16/18: against material from animals or humans - G01N 33/6854: {Immunoglobulins} - G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups - G01N 2333/96455: Kallikrein (3.4.21.34; 3.4.21.35) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support. ## Claims ### Claim 1 A method for treatment of a Type I allergy in a mammal, comprising administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively. ### Claim 2 (depends on 1) The method of claim 1, wherein the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, is administered. ### Claim 3 (depends on 1) The method of claim 1, wherein said mammal is a primate. ### Claim 4 (depends on 1) The method of claim 1, wherein said mammal is selected from the group consisting of humans, cats, horses, cows, pigs, rats and mice. ### Claim 5 (depends on 1) The method according to claim 1, wherein the polypeptide is purified from dog urine. ### Claim 6 (depends on 1) The method according to claim 1, wherein the polypeptide is recombinantly produced. ### Claim 7 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has at least 50 amino acid residues. ### Claim 8 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has at least 75 amino acid residues. ### Claim 9 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has at least 100 amino acid residues. ### Claim 10 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 50%. ### Claim 11 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 60%. ### Claim 12 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 70%. ### Claim 13 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 80%. ### Claim 14 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 90%. ### Claim 15 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment has a sequence identity to the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 of at least 95%. ### Claim 16 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment is a subunit of the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 and has a molecular weight of 10±2 as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). ### Claim 17 (depends on 1) The method according to claim 1, wherein the fragment is administered and the fragment is a subunit of the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1 and has a molecular weight of 18±2 as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). ### Claim 18 A diagnostic kit, comprising the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.